Daunomycin
T-Lymphoblastic Lymphoma
Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Children's Oncology Group
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07072585CT.gov Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) | — | Not Yet Recruiting | — | — | — |
NCT06210750CT.gov Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · T-Lymphoblastic Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Daunomycin (this asset) | Children's Oncology Group | P3 | BB · 66 |
| Vincristine Sulfate | Children's Oncology Group | P3 | BB |
| Pegaspargase | Children's Oncology Group | P3 | BB |
| Asparaginase | University of Washington | P3 | BB |
| Methotrexate | Children's Oncology Group | P3 | BB |
| Cyclophosphamide | Children's Oncology Group | P3 | BB |
| Dexasone | Children's Oncology Group | P3 | BB |
| Mercaptopurine Anhydrous | Children's Oncology Group | P3 | BB |
| Thioguanine Anhydrous | Children's Oncology Group | P3 | BB |
+42 more in the T-Lymphoblastic Lymphoma cohort
Other indications for Daunomycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia By FAB Classification | — | P3 | BBB · 78 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P3 | BBB · 77 |
| Acute Monocytic Leukemia | — | P3 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Daunomycin in T-Lymphoblastic Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/daunomycin-t-lymphoblastic-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →